Bivariate Sequential Designs for Phase II Trials

DOI10.2307/2532952MaRDI QIDQ4855194zbMATH OpenOpenAlexWikidataFDO

Authors Mark R. Conaway, Gina R. Petroni

Publication date 13 December 1995

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.2307/2532952

Mathematics Subject Classification ID

Sequential statistical design (62L05) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cited in

(21)

• Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
• Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
• A curtailed procedure for selecting among treatments with two Bernoulli endpoints
• Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters
• Monitoring the rates of composite events with censored data in phase II clinical trials
• Testing statistical hypotheses on stochastic ordering of discrete distributions
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
• A Bayesian Group Sequential Approach for Multiple Endpoints
• Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm
• On the maximum total sample size of a group sequential test about bivariate binomial propor\-tions
• Exact sequential analysis for multiple weighted binomial end points
• Group sequential designs for clinical trials with bivariate endpoints
• Stopping rules for phase II clinical trials: an overview
• Optimal sequential procedure for early detection of multiple side effects
• Flexible designs for phase II comparative clinical trials involving two response variables
• Repeated significance tests of linear combinations of sensitivity and specificity of a diagnostic biomarker
• Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection
• Flexible bivariate phase II clinical trial design incorporating toxicity and response on different schedules
• Fixed sample size subset selection among treatments with two binary endpoints in comparison with a control

This page was built for publication: Bivariate Sequential Designs for Phase II Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4855194)